Keele, UK, 20 February 2026 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces it is making its SYNICEMTM bone cement products available in the UK with immediate effect.
SYNICEMTM bone cement products have been manufactured for over 25 years by Biocomposites’ subsidiary, Synimed.
Following the launch of SYNICEMTM antibiotic loaded preformed spacers in the UK last year, Biocomposites was already planning to follow this up with the launch of their SYNICEMTM bone cements. This UK launch has been brought forward to help ease the supply crisis that is currently unfolding.
SYNICEMTM bone cement products are CE marked and already fully approved for use in the UK. They are available as high viscosity and low viscosity variants, with and without the antibiotic gentamicin.
Michael Harris, Chief Executive Officer of Biocomposites, said: “The NHS is currently facing an acute bone cement supply crisis, which could lead to thousands of orthopaedic operations such as hip and knee replacements being delayed.
“We at Biocomposites – which is one of the few companies in the world capable of manufacturing bone cement at scale – want to do everything we can to help, so patients do not have to wait any longer than absolutely necessary for their vital operations.
“We have therefore decided to bring forward the launch of our SYNICEMTM bone cement products in the UK with immediate effect, to make them available as soon as possible.
“We are also doubling capacity at our manufacturing facility, principally to help meet UK demand.
“We believe these measures will go a long way to helping meet NHS demand for bone cement and minimising delays to operations.”